SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.51+2.7%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (3952)6/2/2001 1:36:17 PM
From: Vector1  Read Replies (1) of 52153
 
<<On the other hand, getting drugs approved for small indications doesn't cause much excitement. LGND is a prime example>>

I do not necessarily agree that approval for a small indication is a negative. You have to look at the drugs potential. LGND had many problems besides niche indications the most notable was a weak management with little focus. Genzyme created a major pharma business with a drug that was approved for a patient population of under 5000. Celgene's Thalomid has only been approved for a rare form of Leprocy. The real value is off label use for Multiple Myeloma and potentially other metastatic cancers. Many pharmas and biotechs seek approval for a niche indication (especially in oncology)with the expectation of expanding use through additional clinical trials and published papers in respected peer reviewed journals.

V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News